Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CMS Skinhealth has successfully commercialized several innovative drugs in China, including tildrakizumab injection (ILUMETRI) for moderate-to-severe plaque psoriasis and ruxolitinib cream for nonsegmental vitiligo. The company also holds exclusive licenses to multiple regenerative medical aesthetic injectable products currently in registrational clinical trials. Their clinical programs have demonstrated efficacy and safety consistent with global standards; ILUMETRI's PASI75 response rate continued to increase over time in Chinese phase III studies.[1][2][5]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CMS Skinhealth.